Of 2,545 in-patients with primary lung cancer, pathological proof of the diagnosis was obtained by sputum cytology in 48%, by bronchoscopy in 32%, by biopsy from miscellaneous sites in 12%, and at thoracotomy or necropsy only in 19%. The diagnosis was made solely on clinical and radiological evidence in 8%.
Bartholomew's Hospital and 29 from Brompton Hospital could not be traced.
Notes from a total of 2,545 patients were available for study, 913 from St. Bartholomew's and 1,632 from Brompton. There were 2,176 males and 369 (14%) females. One or more specimens of sputum were submitted for cytological investigation from 2,035 (80%) of the patients, bronchoscopy was performed in 1,518 (60%), and biopsies were taken from other sites in 524 (21%). Lung resection was performed in 1,002 (39%) and a further 199 (8%) came to necropsy. A positive pathological diagnosis by means of one or more of these methods was obtained in 2,342 (92%), including 486 (19%) by lung resection or necropsy only. The remaining 203 (8%) were diagnosed by clinical and radiological examination only, no pathological confirmation being obtained. The distribution by cell type for the 2,342 patients was as follows:
Squamous (1-1%)
The miscellaneous group included 10 bronchiolo-623 alveolar cell tumours, six carcinoid adenomata, and various sarcomata and lymphomata.
The records of sputum cytology at both hospitals throughout 1967, selected as the mid-year of the study, were also analysed in order to obtain an overall view of the extent to which the test was used as a diagnostic measure. All such records were included, irrespective of the final diagnosis. At least one specimen of sputum from 1,598 patients was examined during 1967, 528 at St. Bartholomew's and 1,070 at Brompton.
In each hospital routine sputum examination was performed on fresh specimens. The staining at St. Bartholomew's was by the method of Papanicolaou (1942) and at Brompton by methylene blue (Schuster, 1947) . Three specimens of sputum were considered necessary for diagnosis, examination lasting at least 45 minutes before negative reports were issued.
RADIOLOGICAL APPEARANCES
Standard postero-anterior and lateral films, often with tomograms in addition, revealed the primary tumour mass in 1,103 (43%) of the patients (Table  I ). The mass measured more than 2 cm in diameter in most of these (38 %) and was commonly associated with a hilar opacity. The remaining patients had indirect evidence of lung cancer, in the form of collapse/consolidation/effusion, diffuse shadows or root/mediastinal opacities only. Forty-four (2%), all with pathological confirmation of the diagnosis, had postero-anterior films of the chest which showed no suspicion of cancer.
Positive results from sputum cytology were remarkably similar in most radiological groups. The lowest figure (39%) occurred with rounded opacities up to 2 cm across compared with 60% recorded for the larger tumours. This is in keeping with the experience of others (Umiker, 1961; Attar, Naib and Cowley, 1961 ; Hattori, Matsuda, Sugiyama and Matsuda, 1964 The frequency with which primary lung cancer should be diagnosed without radiological evidence is a matter which is unlikely ever to be satisfactorily determined, since all cancers are radiologically invisible in the first instance. Simon (1966) considers that tumours measuring less than 1-3 cm in diameter are unlikely to be detected, and Spratt, Ter-Pogossian and Long (1963) (Woolner, Andersen and Bernatz, 1960; Lerner, Rosbash, Frank and Fleischner, 1961 ; Russell et al., 1963; Melamed, Koss, and Cliffton, 1963 (Farber et al., 1948 ;  Kuesko and Portele, 1949 ; Philps, 1954; Meyer and Umiker, 1961; Hinson and Kuper, 1963; Russell et al., 1963; Melamed and Cahan, 1968) . Those with the highest positivity rates have tended to be from small numbers of patients. By convention, three satisfactory specimens are needed for a considered cytological opinion, giving a figure for this series of 69%.
The figure of 85% positive, obtained for patients who had four or more specimens examined, reflects the effort made to achieve positive results in a group of patients in whom the clinical diagnosis of lung cancer was strongly suspected. The 483 patients in whom the pathological diagnosis was based solely on sputum cytology comprised 40% of the 1,209 patients with malignant cells in the sputum or 24% of the 2,035 patients with specimens examined. The existence of this important group of patients in whom the pathological diagnosis is based solely upon sputum testing has been given little recognition in medical literature. Perhaps in order to ensure accuracy in analysis most published reports have included only patients in whom the diagnosis of primary lung cancer has been confirmed by other means, mainly by bronchoscopy or thoracotomy. Davies (1966) lists such data from 25 series extending from the classic paper of Dudgeon and Wrigley (1935) up to 1963, the rates of positivity varying from 42-8 % to 92-7% of the patients examined. Grunze (1960) reviewed 29 similar series with 40% to 90% positives, giving his own figure of 51 % for 3,662 patients tested. Many of the papers with impressively high rates of positivity have been written by cytologists reporting small personal series or have contained unacceptably high rates of false positives. All are agreed that the greater the number of specimens tested, the greater the likelihood of a positive result, but records of the total number of specimens submitted and the number rejected as unsatisfactory were often omitted from these reports. Latterly, the general opinion seems (Table V) . Central tumours, arising from the main or lobar bronchi, gave a significantly higher rate of positivity than peripheral tumours, namely 57% compared with 4800 (P<O 005).
BRONCHOSCOPIC FINDINGS
Of the 1,518 patients in whom bronchoscopy was performed, no specimen was obtained in 506 (33 %). The remainder had either a bronchial biopsy or a trap specimen or both; of the 801 positives, 752 were from bronchial biopsies, the other 49 being trap specimens when the biopsy was either negative or not taken. These two types of specimen have both been regarded as positive and are analysed together as a measure of the (Table IV; page 623) bronchoscopy showed the expected excess of squamous carcinomata and a very low figure for the mainly peripheral adenocarcinomata. Central tumours yielded many more positive results than peripheral tumours, namely 61 % compared with 28% (Table  V) , a highly significant difference (P<0-001).
The overall figure for bronchoscopic diagnosis in this series was 801 (32%) in 2,545 patients. When the 49 patients who were positive only on trap specimens are deducted, 752 (26%) were positive on bronchial biopsy. Grunze (1960) Jennings and Shaw (1953) Enlarged scalene or cervical nodes, with a positivity rate of 90%, were a valuable source of diagnosis and cell typing, especially when sputum 3A cytology was negative; the total of 140 positives represented 4% of the whole series. Mediastinal nodes also yielded a high number of positives (69%). When the indications for node biopsy in lung cancer are extended the positivity rate tends to fall. Grunze (1960) reported 42% positive when 26% of 438 patients submitted to the procedure. Positivity rates of 5% to 25% have been recorded when impalpable nodes have been removed (Klingenberg, 1964; Blair and Hughes, 1966; Brantigan and Moszkowski, 1966) . Delarue and Strasberg (1966) excised mediastinal nodes from 400 patients with only 30% positive.
The yield of malignant cells in pleural fluids was low (34%) and compares unfavourably with the 54% of Boddington and Spriggs (1965) . Pleural needle biopsy gave only 38% positive results, partly because satisfactory portions of pleura were not always obtained; Donohue, Katz, and Matthews (1958) obtained 38% positives from a similar series. Open pleural biopsy with the excision of a much larger specimen gave 80% positive results. Lung needling was infrequently performed, being virtually reserved for inoperable peripheral growths, and gave the anticipated high rate of positivity (Adamson and Bates, 1967; Steel and Winstanley, 1969) .
Most of the remaining specimens listed in (Jennings and Shaw, 1953) with a small addition from trap specimens. Pathological material from miscellaneous sites is sometimes all that is available for a firm diagnosis; a positive result usually indicates that the growth is beyond the stage of operability.
Sputum cytology has obvious advantages over other methods of diagnosis. It is quick and devoid of trauma and is the test most likely to give a positive result. At times it may be life-saving in terms of early diagnosis. For patients whose disease has proceeded beyond the limits of effective therapy, it is an ideal way of establishing the diagnosis. Unfortunately, it is very demanding in both laboratory time and expertise. A skilled cytologist cannot be expected to search microscope slides efficiently for more than about four and a half hours a day. In this time he might examine 8 to 10 specimens of sputum. The number of positives he finds is likely to be about 15 to 20%, with three-quarters of the specimens coming from patients who do not have lung cancer (Table II) . For these reasons sputum cytology, as practised at present, is unlikely to be adopted as a routine procedure outside large medical centres. Attempts to save time and cost have so far proved disappointing. Technicians may prepare slides and 'screen off' negatives; in rare instances they have become competent cytotechnicians, but the opportunities for them to do so are few. There are many difficulties facing the development of automated cytological screening. Malignant cells may be large or small, are often degenerate, and their nuclei vary in size; the requirement is a method of identifying the ratio of nuclear to cell size. At least two systems based on microspectrophotometric analyses of ceUs are currently being developed (Kamentsky and Melamed, 1969; Finkel, Grand, Ehrlich, and DeCote, 1970) . The hope is that a system will eventually be devised which will bring the benefits of sputum cytology to a much greater number of patients than is possible at present. sputum cytology to cancer with special reference
